A Phase 3 interventional study of Guselkumab and Placebo in Arthritis, Psoriatic, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 280 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing guselkumab in Arthritis, Psoriatic — 5 open to participants now, 8 under way, 3 of them phase 3. guselkumab · Arthritis, Psoriatic.
Among the 14 studies testing guselkumab in Arthritis, Psoriatic, this one has the largest enrollment, is one of 4 that started in 2021, is one of 7 in phase 3, and was the 5th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →5 of the 14 studies testing guselkumab in Arthritis, Psoriatic are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
NYU Langone Health · Sites in United States
Ages 18+
Johnson & Johnson Private Limited · Sites in India
Ages 18+
University of California, San Diego · Sites in United States
Janssen Research & Development, LLC · Sites in United States, Argentina, Australia and 15 more countries
Ages 3+
By country, each count listing its studies:
guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,054 is above the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 173 across the 14 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 14 have an industry lead sponsor. The 6 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
37 studies in Arthritis, Psoriatic by Johnson & Johnson: 5 open now, 13 under way, 5 of them phase 3. Of 23 finished, 13 (57%) have results posted.
Among the 37 studies in Arthritis, Psoriatic by Johnson & Johnson, this one has the largest enrollment of the 25 interventional ones that give a count, is one of 7 that started in 2021, is one of 15 in phase 3, reaches primary completion later than 0 of the 12 other live ones, and was the 23rd registered.
Johnson & Johnson’s Arthritis, Psoriatic studies by the year they started, since 2002.
4 of the studies testing guselkumab in Arthritis, Psoriatic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04929210Janssen Research & Development, LLCA Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease | 2027-04-01 |
| NCT07141004Johnson & Johnson Private LimitedA Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA) | 2027-06-05 |
| NCT07654751Janssen Research & Development, LLCA Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | 2027-08-31 |
| NCT06586281University of California, San DiegoElucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 14 studies testing guselkumab in Arthritis, Psoriatic, from their registry updates:
Among Johnson & Johnson’s 37 in Arthritis, Psoriatic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive guselkumab and placebo subcutaneously (SC) to maintain the blind. Participants who have not discontinued will be eligible to enter a long-term extension (LTE) and will receive guselkumab and placebo SC. After the study is unblinded to the investigative sites, participants will receive guselkumab and no longer be required to dose with placebo to maintain the blind.
Drug: Guselkumab · Drug: Placebo
Participants will receive guselkumab SC. Participants who have not discontinued will be eligible to enter an LTE and will receive guselkumab SC.
Drug: Guselkumab
Participants will receive placebo SC and will cross over to receive SC guselkumab. Participants who have not discontinued will be eligible to enter an LTE and will receive guselkumab SC.
Drug: Guselkumab · Drug: Placebo
Participants will receive guselkumab as SC injection.
Also known as: CNTO 1959
Participants will receive matching placebo as SC injection.
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24
ACR 20 response: \>=20% improvement from baseline (bl) in both swollen (66 joints), tender (68 joints) joint count, \>=20% improvement from bl in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100mm, 0=no pain, 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100mm, 0=excellent, 100=poor), physician's global assessment of disease activity (VAS; 0-100mm, 0=no arthritis activity,100=extremely active arthritis), HAQ-DI (questionnaire assessing 8 functional areas; 0-3, 0=no difficulty, 3=inability to perform task in area), and CRP. Natural Disaster (ND)-site inaccessible due to COVID-19. Major Disruption (MD)-disruption involving Ukraine and neighboring countries/territories. Intercurrent event (ICE) handling: Composite-discontinue study drug not due to ND/MD, initiate/increase DMARD/oral corticosteroid, initiate prohibited PsA treatment; Hypothetical-discontinue/severe noncompliance of study drug due to ND/MD.
Time frame: At Week 24
Change From Baseline in Psoriatic Arthritis (PsA) Modified Van Der Heijde-Sharp (vdH-S) Total Score at Week 24
Modified vdH-S score was sum of erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score was total erosion severity in 40 joints of 2 hands and 12 joints of 2 feet, maximum erosion score=320. Each hand joint was scored on 0 to 5 with 0 =no erosion, 5 =complete collapse of bone. Foot joint was scored on 0 to 10, 0 =no erosion, 10 =complete collapse of bone. JSN score was total JSN score in same 52 joints, each joint scored on 0 to 4 with 0 indicating no JSN, and 4 indicating absence of joint space, maximum JSN score=208. Maximum modified vdH-S score=528. Higher score =severe structural destruction and complete loss of joint spaces. Natural Disaster (ND)-site inaccessible due to COVID-19. Major Disruption (MD)-disruption involving Ukraine and neighboring countries/territories. Intercurrent event (ICE) handling: Hypothetical-discontinue/severe noncompliance of study drug due to ND/MD
Time frame: Baseline (after first administration of study drug) and Week 24
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Time frame: From baseline (after first administration of study drug) up to 168 weeks
Number of Participants With Serious Adverse Events (SAEs)
Time frame: From baseline (after first administration of study drug) up to 168 weeks
Number of Participants With Reasonably Related Adverse Events (AEs)
Time frame: From baseline (after first administration of study drug) up to 168 weeks
Number of Participants With TEAEs Leading to Discontinuation of Study Intervention
Time frame: From baseline (after first administration of study drug) up to 168 weeks
Number of Participants With Treatment Emergent Infections
Time frame: From baseline (after first administration of study drug) up to 168 weeks
Number of Participants With Injection-site Reactions Leading to Discontinuation of Study Intervention
Time frame: From baseline (after first administration of study drug) up to 168 weeks
Number of Participants With Clinical Laboratory Abnormalities
Time frame: From baseline (after first administration of study drug) up to 168 weeks
Number of Participants With Maximum Common Terminology Criteria for Adverse Events (CTCAE) Toxicity Grade Laboratory Values
Time frame: From baseline (after first administration of study drug) up to 168 weeks
Serum Guselkumab Concentration
Time frame: From baseline (after first administration of study drug) up to 168 weeks
Number of Participants With Anti-guselkumab Antibodies
Time frame: From baseline (after first administration of study drug) up to 168 weeks
| Milestone | Group 1: Guselkumab 100 mg q8w | Group 2: Guselkumab 100 mg q4w | Group 3: Placebo Followed by Guselkumab |
|---|---|---|---|
| Started | 388 | 280 | 386 |
| Modified full analysis set | 371 | 273 | 376 |
| Completed | 370 | 270 | 372 |
| Not completed | 18 | 10 | 14 |
| Withdrew: Adverse event | 7 | 2 | 1 |
| Withdrew: Death | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 2 | 3 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 6 | 1 | 9 |
| Withdrew: Subject refused further study treatment | 1 | 0 | 0 |
| Withdrew: Other | 2 | 2 | 1 |
ACR 20 response: \>=20% improvement from baseline (bl) in both swollen (66 joints), tender (68 joints) joint count, \>=20% improvement from bl in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100mm, 0=no pain, 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100mm, 0=excellent, 100=poor), physician's global assessment of disease activity (VAS; 0-100mm, 0=no arthritis activity,100=extremely active arthritis), HAQ-DI (questionnaire assessing 8 functional areas; 0-3, 0=no difficulty, 3=inability to perform task in area), and CRP. Natural Disaster (ND)-site inaccessible due to COVID-19. Major Disruption (MD)-disruption involving Ukraine and neighboring countries/territories. Intercurrent event (ICE) handling: Composite-discontinue study drug not due to ND/MD, initiate/increase DMARD/oral corticosteroid, initiate prohibited PsA treatment; Hypothetical-discontinue/severe noncompliance of study drug due to ND/MD.
| percentage of participants | Group 1: Guselkumab 100 mg q8w | Group 2: Guselkumab 100 mg q4w | Group 3: Placebo Followed by Guselkumab |
|---|---|---|---|
| Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 | 68.3 | 66.6 | 47.0 |
Modified vdH-S score was sum of erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score was total erosion severity in 40 joints of 2 hands and 12 joints of 2 feet, maximum erosion score=320. Each hand joint was scored on 0 to 5 with 0 =no erosion, 5 =complete collapse of bone. Foot joint was scored on 0 to 10, 0 =no erosion, 10 =complete collapse of bone. JSN score was total JSN score in same 52 joints, each joint scored on 0 to 4 with 0 indicating no JSN, and 4 indicating absence of joint space, maximum JSN score=208. Maximum modified vdH-S score=528. Higher score =severe structural destruction and complete loss of joint spaces. Natural Disaster (ND)-site inaccessible due to COVID-19. Major Disruption (MD)-disruption involving Ukraine and neighboring countries/territories. Intercurrent event (ICE) handling: Hypothetical-discontinue/severe noncompliance of study drug due to ND/MD
| Score on a scale | Group 1: Guselkumab 100 mg q8w | Group 2: Guselkumab 100 mg q4w | Group 3: Placebo Followed by Guselkumab |
|---|---|---|---|
| Change From Baseline in Psoriatic Arthritis (PsA) Modified Van Der Heijde-Sharp (vdH-S) Total Score at Week 24 | 0.54 (0.14 to 0.95) | 0.55 (0.10 to 1.00) | 1.35 (0.94 to 1.75) |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over All cause mortality, SAEs, and non-SAEs: From baseline (after first administration of study drug) up to 24 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: Guselkumab 100 mg q8w | 0/388 (0%) | 12/388 (3.1%) | 41/388 (10.6%) |
| Group 2: Guselkumab 100 mg q4w | 1/280 (0.4%) | 5/280 (1.8%) | 22/280 (7.9%) |
| Group 3: Placebo Followed by Guselkumab | 0/386 (0%) | 10/386 (2.6%) | 42/386 (10.9%) |
| Event | Group 1: Guselkumab 100 mg q8w | Group 2: Guselkumab 100 mg q4w | Group 3: Placebo Followed by Guselkumab |
|---|---|---|---|
| PneumoniaInfections and infestations | 2/388 | 0/280 | 0/386 |
| Covid-19Infections and infestations | 1/388 | 1/280 | 1/386 |
| DiverticulitisInfections and infestations | 0/388 | 1/280 | 0/386 |
| Tendon RuptureInjury, poisoning and procedural complications | 0/388 | 1/280 | 0/386 |
| EndometriosisReproductive system and breast disorders | 0/388 | 1/280 | 0/386 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 1/388 | 1/280 | 0/386 |
| Atrial FibrillationCardiac disorders | 0/388 | 0/280 | 1/386 |
| CholelithiasisHepatobiliary disorders | 0/388 | 0/280 | 1/386 |
| Clavicle FractureInjury, poisoning and procedural complications | 0/388 | 0/280 | 1/386 |
| Humerus FractureInjury, poisoning and procedural complications | 0/388 | 0/280 | 1/386 |
| Event | Group 1: Guselkumab 100 mg q8w | Group 2: Guselkumab 100 mg q4w | Group 3: Placebo Followed by Guselkumab |
|---|---|---|---|
| Upper Respiratory Tract InfectionInfections and infestations | 20/388 | 15/280 | 22/386 |
| Covid-19Infections and infestations | 22/388 | 8/280 | 20/386 |
| Age, Continuous(years) | Group 1: Guselkumab 100 mg q8w | Group 2: Guselkumab 100 mg q4w | Group 3: Placebo Followed by Guselkumab | Total |
|---|---|---|---|---|
| Mean | 52.9 ± 13.03 | 52.3 ± 13.15 | 53.4 ± 12.92 | 52.9 ± 13.02 |
| Age, Customized(Participants) | Group 1: Guselkumab 100 mg q8w | Group 2: Guselkumab 100 mg q4w | Group 3: Placebo Followed by Guselkumab | Total |
|---|---|---|---|---|
| Adults (18-64 years) | 311 | 229 | 304 | 844 |
| From 65 to 84 years | 77 | 51 | 82 | 210 |
| 85 years and over | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Group 1: Guselkumab 100 mg q8w | Group 2: Guselkumab 100 mg q4w | Group 3: Placebo Followed by Guselkumab | Total |
|---|---|---|---|---|
| Female | 182 | 127 | 170 | 479 |
| Male | 206 | 153 | 216 | 575 |
| Ethnicity (NIH/OMB)(Participants) | Group 1: Guselkumab 100 mg q8w | Group 2: Guselkumab 100 mg q4w | Group 3: Placebo Followed by Guselkumab | Total |
|---|---|---|---|---|
| Hispanic or Latino | 6 | 4 | 8 | 18 |
| Not Hispanic or Latino | 382 | 276 | 378 | 1036 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group 1: Guselkumab 100 mg q8w | Group 2: Guselkumab 100 mg q4w | Group 3: Placebo Followed by Guselkumab | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 2 | 2 |
| Asian | 61 | 38 | 61 | 160 |
| Native Hawaiian or Other Pacific Islander | 2 | 2 | 0 | 4 |
| Black or African American | 2 | 0 | 0 | 2 |
| White | 322 | 240 | 321 | 883 |
| More than one race | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 1 | 0 | 1 | 2 |
| Region of Enrollment(Participants) | Group 1: Guselkumab 100 mg q8w | Group 2: Guselkumab 100 mg q4w | Group 3: Placebo Followed by Guselkumab | Total |
|---|---|---|---|---|
| Australia | 3 | 3 | 3 | 9 |
| Bosnia and Herzegovina | 24 | 13 | 25 | 62 |
| Bulgaria | 32 | 28 | 35 | 95 |
| Canada | 3 | 1 | 1 | 5 |
| China | 25 | 17 | 27 | 69 |
| Croatia | 8 | 2 | 5 | 15 |
| Estonia | 3 | 2 | 5 | 10 |
| Georgia | 37 | 30 | 33 | 100 |
| Germany | 4 | 1 | 0 | 5 |
| Greece | 1 | 0 | 1 | 2 |
| Hungary | 5 | 10 | 10 | 25 |
| Israel | 6 | 2 | 7 | 15 |
| Italy | 3 | 2 | 2 | 7 |
| Latvia | 13 | 4 | 4 | 21 |
| Lithuania | 16 | 15 | 23 | 54 |
| Malaysia | 4 | 2 | 5 | 11 |
| Philippines | 32 | 18 | 23 | 73 |
| Poland | 38 | 25 | 27 | 90 |
| Russian Federation | 20 | 16 | 19 | 55 |
| Serbia | 27 | 20 | 28 | 75 |
| Slovakia | 6 | 6 | 6 | 18 |
| Slovenia | 1 | 1 | 0 | 2 |
| Korea, South | 0 | 0 | 1 | 1 |
| Spain | 9 | 9 | 14 | 32 |
| Taiwan | 1 | 1 | 3 | 5 |
| Turkey | 1 | 0 | 1 | 2 |
| Ukraine | 35 | 25 | 39 | 99 |
| United States | 10 | 11 | 13 | 34 |
| Czech Republic | 21 | 16 | 26 | 63 |
Showing the first 100 of 280 sites across 29 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinicaltrials/ transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Jun 2021 to primary completion in Dec 2024, 42 months.
Results were first posted in Feb 2026, 1 year 1 month after primary completion.
Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 42 months is above that.
Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Guselkumab
Janssen Research & Development, LLC →